Mitazalimab is an FcγR-dependent CD40 agonist with tumor-targeting activity; it activates antigen-presenting cells, such as dendritic cells (DCs), to initiate tumor-reactive T cells, thereby inducing tumor-specific T cell infiltration and tumor cell killing; it also remodels the tumor-infiltrating myeloid microenvironment.